Skip Navigation

Post-traumatic Stress Disorder (PTSD) in Women: Evaluating the Efficacy of CRF1 Antagonist GSK561679

Principal Investigator:Boadie Dunlop, MD
Population: Women aged 18-65 with Post-traumatic stress disorder (PTSD)
Summary:  Eligible patients will receive 6 weeks of treatment with either a CRF1 (Corticotropin-Releasing Factor type 1) receptor antagonist (GSK561679) or placebo (1:1 randomization), followed by one month of follow-up care.
Procedures: Startle testing; neuropsychological testing, blood draws
Telephone (MAP Line): 404-778-6663 (MOOD)
Patients can go to: